Accelerate Diagnostics, Inc. (AXDX) News
Filter AXDX News Items
AXDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AXDX News Highlights
- AXDX's 30 day story count now stands at 3.
- Over the past 3 days, the trend for AXDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ROSE are the most mentioned tickers in articles about AXDX.
Latest AXDX News From Around the Web
Below are the latest news stories about ACCELERATE DIAGNOSTICS INC that investors may wish to consider to help them evaluate AXDX as an investment opportunity.
Accelerate Diagnostics Inc. (NASDAQ: AXDX): Is Its Value Too High Compared To Others?Accelerate Diagnostics Inc. (NASDAQ:AXDX) shares, rose in value on Friday, 12/30/22, with the stock price up by 12.33% to the previous day’s close as strong demand from buyers drove the stock to $0.71. Actively observing the price movement in the last trading, the stock closed the session at $0.63, falling within a range of $0.5182 … Accelerate Diagnostics Inc. (NASDAQ: AXDX): Is Its Value Too High Compared To Others? Read More » |
How should investors view Accelerate Diagnostics Inc. (AXDX)?The share price of Accelerate Diagnostics Inc. (NASDAQ:AXDX) fell to $0.51 per share on Tuesday from $0.57. While Accelerate Diagnostics Inc. has underperformed by -10.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AXDX fell by -89.78%, with highs and lows ranging from $5.59 to $0.50, […] |
Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kitAccelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit. Included in the submission are additional escalation and de-escalation agents for Gram-negative organisms, additional antibiotics for Acinetobacter baumannii, and breakpoint updates. These updates add oral de-escalation antibiotic options for clinicians to use, which can assist with |
Accelerate Diagnostics Inc. (NASDAQ:AXDX) Shares Dropped -15.50% In A Week. Can It Continue Rising?In last trading session, Accelerate Diagnostics Inc. (NASDAQ:AXDX) saw 0.42 million shares changing hands with its beta currently measuring 1.17. Company’s recent per share price level of $0.95 trading at $0.0 or 0.03% at ring of the bell on the day assigns it a market valuation of $90.74M. That closing price of AXDX’s stock is … Accelerate Diagnostics Inc. (NASDAQ:AXDX) Shares Dropped -15.50% In A Week. Can It Continue Rising? Read More » |
Accelerate Diagnostics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagAccelerate Diagnostics ( NASDAQ:AXDX ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.96m (down 5.2... |
Accelerate Diagnostics falls after missing Q3 revenue consensus, lowering guidanceIn vitro diagnostics company Accelerate Diagnostics (AXDX) fell ~15% after reporting a miss in Q3 revenue and lowering FY22 guidance. |
Accelerate Diagnostics Reports Third Quarter 2022 Financial ResultsTUCSON, Ariz., Nov. 14, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022. "Our third quarter results were generally in line with my expectations," commented Jack Phillips, Chief… |
Accelerate Diagnostics, Inc. (AXDX) Q3 2022 Earnings Call TranscriptAccelerate Diagnostics, Inc. (NASDAQ:NASDAQ:AXDX) Q3 2022 Earnings Conference Call November 14, 2022, 16:30 ET Company Participants Laura Pierson - IR Officer Jack Phillips - CEO, President… |
Accelerate Diagnostics GAAP EPS of -$0.18, revenue of $2.96M (NASDAQ:AXDX)Accelerate Diagnostics press release (AXDX): Q3 GAAP EPS of -$0.18.Revenue of $2.96M (-5.1% Y/Y).Gross margin was 26% for the quarter, compared to 32% in the second quarter of the… |
Accelerate Diagnostics Q3 2022 Earnings PreviewAccelerate Diagnostics (AXDX) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close.The consensus EPS Estimate is -$0.18 (-20.0% Y/Y) and the… |